English
Specials
    Upgrade
    MoneycontrolBe a PRO
    Moneycontrol PRO
    you are here: HomeNewsBusinessMoneycontrol Research

    Cipla — Large part of COVID opportunity has played out

    In the US market, Albuterol opportunity remains a key lever for Cipla at least till the time Perrigo re-enters although in terms of market share, the drugmaker may be close to maturity

    Anubhav Sahu
    January 31, 2021 / 01:23 PM IST
    Cipla — Large part of COVID opportunity has played out

    PRO Only Highlights
    -      Quarterly performance largely backed by improved realisations
    -      Medium-term triggers China plus and protectionist measures for tyre industry
    -      Valuations not inexpensive; but improved medium-term outlook

    Highlights - Strong performance led by India - In US, Albuterol gains are offset by a product recall -Next drug to watch is Advair, used in the management of pulmonary disease - Margins likely to moderate as operating expenses pick up Cipla (CMP: Rs 826; Market cap: Rs 66,606 crore) — the world’s second largest seller of inhalers — has posted another strong quarter, helped by its respiratory portfolio. The resultant cash flow has helped the company repay loan worth $137 million ahead of schedule and Rs...

    • PRO Panorama

      Moneycontrol Pro Panorama | Banking crisis: Will Powell pause?

      Mar 22, 2023 / 03:09 PM IST

      In today’s edition of Moneycontrol Pro Panorama: India likely to maintain growth momentum, gold is back in the limelight, China'...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender: Between the Fed and a hard place

      Mar 11, 2023 / 11:38 AM IST

      The Fed is caught between combating inflation and worries over a financial mishap

      Read Now

    To read the full story, Subscribe to Moneycontrol PRO

    Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

    View Plans

    Already a member? Sign in

    Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

    50% OFF

    What Do You Get

    • Ad free experience

      Experience a non-intrusive navigation and faster response in the ad free mode

    • Sharpest Opinions

      Access to 230+ exclusive stories per month from our editorial and Experts

    • +

      Have a Global edge with access to content from world renowned experts and journalist

    • Actionable Insights

      Access to 40+ weekly investment ideas including 4 daily technical calls

    • Virtual Events

      Exclusive access to live webinars from market experts on trading and investment strategies

    • Newsletters

      Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

    View Offers

    Get upto 50% discount on limited period offers